GlassScriptPhysician profile
Michael Allen Rudoff
NPI 1134570690
$3,839.82
in general payments reported to CMS, 2019-2025
37 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $231 · 2021: $299 · 2022: $703 · 2023: $366 · 2024: $442 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792 · Education: $24.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.06 |
| Education | $24.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $578.43 | 2019-2025 | Spaceoar Vue System - 10ml, Rezum Generator, General - Kidney Stone Disease |
| Teleflex LLC | $474.47 | 2022-2025 | Urolift, Barrigel |
| Allergan, INC. | $363.61 | 2019-2022 | |
| Coloplast Corp | $321.87 | 2019-2025 | Porges Coloplast, Speedicath |
| Urogen Pharma, INC. | $211.13 | 2021-2025 | |
| Procept Biorobotics Corporation | $202.96 | 2022-2025 | Aquabeam System |
| Medtronic, INC. | $149.60 | 2023-2025 | Interstim |
| Sumitomo Pharma America, INC. | $144.32 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $140.01 | 2021-2022 | |
| Smith+Nephew, INC. | $120.20 | 2019 | |
| Myriad Genetic Laboratories, INC. | $113.09 | 2021-2023 | Prolaris |
| Endo Pharmaceuticals INC. | $107.21 | 2019-2023 | Xiaflex |
| Janssen Biotech, INC. | $106.23 | 2021-2023 | Erleada |
| Johnson & Johnson Health Care Systems INC. | $92.99 | 2019 | |
| Myovant Sciences INC. | $89.39 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calyxo, INC. | $58.80 | 2025 | Cvac Aspiration System |
| Merck Sharp & Dohme LLC | $57.78 | 2022 | |
| Axonics, INC. | $52.35 | 2022-2024 | Axonics, Bulkamid |
| 180 Medical, INC. | $45.73 | 2022-2025 | |
| Abbvie INC. | $42.27 | 2022-2025 | |
| Tolmar Pharmaceuticals, INC. | $37.70 | 2022 | |
| Medtronic USA, INC. | $36.94 | 2019 | |
| Ethicon US, LLC | $32.33 | 2025 | Harmonic, Echelon; Endopath |
| Dendreon Pharmaceuticals LLC | $28.10 | 2021 | |
| Ferring Pharmaceuticals INC. | $24.70 | 2025 | Adstiladrin |
| Rochester Medical Corporation | $24.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.42 | 2025 | |
| Endo USA, INC. | $21.14 | 2024 | Xiaflex |
| Immunitybio, INC. | $17.65 | 2025 | |
| Abc Home Medical Supply, INC. | $17.09 | 2025 | |
| Srs Medical Systems, INC. | $16.40 | 2022 | |
| Laborie Medical Technologies Corp. | $16.14 | 2023 | |
| Photocure INC | $15.82 | 2024 | Cysview |
| Blue Earth Diagnostics | $15.35 | 2019 | |
| Urovant Sciences INC | $15.28 | 2022 | |
| Davol INC. | $13.10 | 2024 | Arista Ah Flexitip |
| Eisai INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rudoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.